18 and older, any sex, with Covid19 or Anosmia. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number of Subjects With COVID-19 Symptoms at Day 3.Primary· Day 3
Number of subjects with any of the following COVID-19 symptoms: fever (temperature \> 38 degrees), cough, shortness of breath or anosmia, at day 3.
Group
Value
95% CI
Hesperidin 1000mg
93
Placebo 1000mg
90
Hesperidin 1000mg
9
Placebo 1000mg
13
Number of Subjects With COVID-19 Symptoms at Day 7.Primary· Day 7
Number of subjects with any of the following COVID-19 symptoms: fever (temperature \> 38 degrees), cough, shortness of breath or anosmia, at day 7.
Group
Value
95% CI
Hesperidin 1000mg
74
Placebo 1000mg
76
Hesperidin 1000mg
17
Placebo 1000mg
25
Number of Subjects With COVID-19 Symptoms at Day 10.Primary· Day 10
Number of subjects with any of the following COVID-19 symptoms: fever (temperature \> 38 degrees), cough, shortness of breath or anosmia, at day 10.
Group
Value
95% CI
Hesperidin 1000mg
58
Placebo 1000mg
60
Hesperidin 1000mg
32
Placebo 1000mg
39
Number of Subjects With COVID-19 Symptoms at Day 14.Primary· Day 14
Number of subjects with any of the following COVID-19 symptoms: fever (temperature \> 38 degrees), cough, shortness of breath or anosmia, at day 14.
Group
Value
95% CI
Hesperidin 1000mg
39
Placebo 1000mg
55
Hesperidin 1000mg
40
Placebo 1000mg
39
Mean Number of COVID-19 Symptoms at Day 3.Secondary· Day 3
Mean number of COVID-19 symptoms (range 0-13) at day 3.
Group
Value
95% CI
Hesperidin 1000mg
4.74
± 2.52
Placebo 1000mg
4.16
± 2.39
Mean Number of COVID-19 Symptoms at Day 7.Secondary· Day 7
Mean number of COVID-19 symptoms (range 0-13) at day 7.
Group
Value
95% CI
Hesperidin 1000mg
3.13
± 2.49
Placebo 1000mg
2.96
± 2.46
Mean Number of COVID-19 Symptoms at Day 10.Secondary· Day 10
Mean number of COVID-19 symptoms (range 0-13) at day 10.
Group
Value
95% CI
Hesperidin 1000mg
2.01
± 2.19
Placebo 1000mg
1.95
± 2.12
Mean Number of COVID-19 Symptoms at Day 14.Secondary· Day 14
Mean number of COVID-19 symptoms (range 0-13) at day 14.
Group
Value
95% CI
Hesperidin 1000mg
1.38
± 1.76
Placebo 1000mg
1.40
± 1.65
Number of Subjects With Complete Disappearance of Any Symptom.Secondary· From randomization to occurence of first event, assessed up to 14 days
The descriptive statistics are the number of participants having complete disappearance of any symptom.
Group
Value
95% CI
Hesperidin 1000mg
29
Placebo 1000mg
33
Hesperidin 1000mg
77
Placebo 1000mg
73
Number of Subjects With the Cough Symptom.Secondary· Day 3
Number of subjects with the cough symptom at day 3.
Group
Value
95% CI
Hesperidin 1000mg
54
Placebo 1000mg
54
Hesperidin 1000mg
48
Placebo 1000mg
49
Number of Subjects With the Cough Symptom.Secondary· Day 7
Number of subjects with the cough symptom at day 7.
Group
Value
95% CI
Hesperidin 1000mg
37
Placebo 1000mg
45
Hesperidin 1000mg
54
Placebo 1000mg
57
Number of Subjects With the Cough Symptom.Secondary· Day 10
Number of subjects with the cough symptom at day 10.
Group
Value
95% CI
Hesperidin 1000mg
26
Placebo 1000mg
35
Hesperidin 1000mg
64
Placebo 1000mg
65
Adverse events — posted to ClinicalTrials.gov
Time frame: Adverse event data were collected between randomization/baseline until the end of study visit (up to 14 days)..
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The main aim of this study is to determine the effects of short-term treatment with hesperidin on COVID-19 symptoms in comparison with a placebo. Treatment effects will be observed through a symptoms diary that will be completed by participants throughout the study and by taking the oral temperature daily.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07452562 — Hesperidin RCT in MS
· NA
· recruiting
NCT06402032 — Clinical and Histological Evaluation of Hesperidin as a Direct Pulp Capping Material
· NA
· completed
NCT04316390 — Influence of Hesperidin and Vitamin C on Uric Acid Concentration
· NA
· completed
NCT03377140 — The Effects of Hesperidin on Biochemical Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease
· NA
· unknown
Other recruiting trials for Covid19
Currently open trials in the same condition.
NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix
· EARLY_PHASE1
· active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation
· NA
· recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs
· NA
· active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry
· recruiting
NCT04806061 — Urine Alkalinisation in COVID-19
· NA
· active not recruiting
Other Montreal Heart Institute trials
Trials by the same sponsor.
NCT07524335 — Aspirin in Subclinical Coronary Artery Disease: A Pilot Randomised Controlled Trial
· Phase 3
· not yet recruiting
NCT07257198 — Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone
· Phase 3
· recruiting
NCT07391358 — DAPT Strategy in HBR Patients Undergoing Complex PCI Following ACS: Second-Phase Beta Testing of a Patients Decision Aid
· NA
· not yet recruiting
NCT05450328 — Inhaled Milrinone and Epoprostenol for the Prevention of Difficult Cardiac Pulmonary Bypass Separation
· Phase 2
· not yet recruiting
NCT07144722 — Prehabilitation Program for Patients Awaiting Elective Heart Surgery at Increased Risk of Postoperative Complications: F
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Montreal Heart Institute
Last refreshed: 8 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04715932.